Showing 15 posts of 736 posts found.

GSK announces extension of FDA’s review for momelotinib

June 20, 2023
Medical Communications FDA, GSK, Oncology, momelotinib, new drug application

GSK has announced that the US Food and Drug Administration (FDA) has extended its review period for the new drug …


GSK’s RSV vaccine approved in EU for older adults

June 7, 2023
Medical Communications EU, GSK, Infections and infestations, RSV, Vaccine

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial virus (RSV) vaccine for active …

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

June 6, 2023
Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates

May 9, 2023
Medical Communications CureVac, GSK, Virology, clinical trial, mrna, vaccines

CureVac and GSK have announced that the first patient in the phase 1 section of their combined phase 1/2 trial …

GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs

June 22, 2021
Manufacturing and Production GSK, HIV, ViiV Healthcare

ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …

AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions

June 7, 2021
Sales and Marketing AstraZeneca, GSK, court

AstraZeneca has launched a court case against Glaxo Smith Kline (GSK), in a claim that could reach hundreds of millions …

GSK building

EMA begin review of GSK & Vir COVID-19 treatment

May 10, 2021
Sales and Marketing COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir

The EMA has begun a rolling review of GSK and Vir’s sotrovimab treatment for COVID-19, which will continue until there …

GSK building

GSK lupus treatment approved by European Commission

May 6, 2021
GSK, Lupus, lupus treatment, pharma, pharma news

GSK’s Benlysta treatment, for patients with active lupus nephritis (LN) in addition to systemic lupus erythematosus (SLE), has been approved …

EMA to begin review of GSK and Vir’s COVID-19 treatment

April 16, 2021
Medical Communications COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir

The EMA have begun a review of GSK and Vir Biotechnology’s investigational COVID-19 antibody (VIR-7831) for patients at high risk …


GSK to support manufacture of 60m Novavax COVID-19 vaccines

March 30, 2021
Manufacturing and Production COVID-19, GSK, UK, Vaccine

GSK has reached an agreement with Novavax and the UK Government Vaccines Taskforce to support the production of up to …

GSK building

GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial

March 29, 2021
Sales and Marketing COVID-19, GSK, Phase III trial, covid-19 treatment, vir

GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …


GSK starts Phase III study for severe asthma treatment

March 18, 2021
GSK, asthma, phase III

GSK has announced today that the first patient has been dosed in part of their Phase III clinical trial investigating …

Medicago & GSK start plant-derived COVID-19 vaccine trial

March 17, 2021
Research and Development COVID-19, GSK

Medicago and GSK have announced the start of Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine. The vaccine candidate …

GSK building

GSK and Vir Biotechnology COVID-19 drug found to reduce deaths and hospitalisation by 85%

March 11, 2021
GSK, GlaxoSmithKline, Vir Biotechnology

Vir Biotechnology and GSK have announced that their monoclonal-antibody drug has been found to reduce hospitalisations or deaths from COVID-19 …

GSK building

GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s

February 26, 2021
Medical Communications COVID-19, GSK, coronavirus, covid-19 treatment, otilimab

GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has shown promising results in older …

Latest content